Skip to content

Apogee Therapeutics, Inc. APGE Financing Cash Flow

Financing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
-$3.47B-351%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$802.2M+26.3%
AbbVie logo
AbbVieABBV
$919M+173%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$3.8M-50.5%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX

Other financials

Income statement

See full
Operating income-$82.8M-31.2%
Net income-$74.1M-33.9%
EPS (diluted)-$1.06-11.6%

Balance sheet

See full
Cash & equivalents$451.8M+323%
Total debt$8.0M-31.9%
Total assets$1.3B+81.1%

Cash flow

See full
Operating cash flow-$55.6M-14.6%
CapEx$62.0K
Free cash flow-$62.8M+7.3%

Valuation

See full
Market cap$6.81B+189%
Enterprise value$6.37B+181%

Returns & leverage

See full
Current ratio32.6×+16.8×

Where this comes from

Reported directly by Apogee Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Apogee Therapeutics, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Apogee Therapeutics, Inc.'s financing cash flow?
Apogee Therapeutics, Inc. (APGE) reported financing cash flow of $411.17M in Q1 2026.
How has Apogee Therapeutics, Inc.'s financing cash flow changed year-over-year?
Apogee Therapeutics, Inc.'s financing cash flow increased by 66004.0% year-over-year, from $622K to $411.17M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.